{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/corticosteroids-inhaled/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"2f4cdb72-e152-55d0-ae30-3f5af0898296","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 228b06ab-4ed0-4d2e-902d-bec4c00e4962 --><h2>Changes</h2><!-- end field 228b06ab-4ed0-4d2e-902d-bec4c00e4962 -->","summary":null,"htmlStringContent":"<!-- begin item 926a953e-45b9-44b2-9528-247a7c3537aa --><!-- begin field 0c015ce3-dd0f-423b-a6a8-ce4055b21a03 --><p><strong>May 2020 </strong>— reviewed. A literature search was conducted in May 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. </p><!-- end field 0c015ce3-dd0f-423b-a6a8-ce4055b21a03 --><!-- end item 926a953e-45b9-44b2-9528-247a7c3537aa -->","topic":{"id":"754932e3-62ea-5d15-b61d-d5a5d6f4fe71","topicId":"702fbe32-706c-43c3-bc60-c5cc8f25f0a7","topicName":"Corticosteroids - inhaled","slug":"corticosteroids-inhaled","lastRevised":"Last revised in May 2020","chapters":[{"id":"e16eda3c-cfc9-5314-bbcf-81f1103a5e06","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"efb2ce33-0722-5c31-9322-cba88887d787","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"39f35fad-0659-5902-87b2-552b35242d2d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2f4cdb72-e152-55d0-ae30-3f5af0898296","slug":"changes","fullItemName":"Changes"},{"id":"efff15e7-d3fb-5f90-b3f8-6e71440ba7a9","slug":"update","fullItemName":"Update"}]},{"id":"1cb3cdc7-d58b-55c4-a4dc-45e54579d133","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"416f2419-bb3a-58d9-aea2-5f7507d47ae6","slug":"goals","fullItemName":"Goals"},{"id":"f0acbcc7-6859-5e5a-97f1-55768a7a7112","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e5608261-290b-5500-aec0-ba1898b40aa8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"627a8419-15f6-51a5-bd61-09cd8079faaa","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"8650965c-ede6-5616-a913-25e614b34788","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a1969d6e-782d-5f6b-aa7a-865b57819d63","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d64ef1a8-021d-5652-a94f-b6a774c0859a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"09abff45-ce37-5d8b-aa7a-22ccb00d395b","slug":"definition","fullItemName":"Definition"},{"id":"05a81ed7-5f38-5cdb-9632-25d4c2e2bdcc","slug":"action-of-inhaled-corticosteroids","fullItemName":"Action of inhaled corticosteroids"},{"id":"64e8ade1-73c2-542d-b449-ad660d98768b","slug":"types-of-inhaled-corticosteroids","fullItemName":"Types of inhaled corticosteroids"}]},{"id":"91b69720-7ebf-581e-982f-dbdd23431ed6","fullItemName":"Management","slug":"management","subChapters":[{"id":"a547f7e2-e032-5c44-8261-cea196fc4d68","slug":"corticosteroids-inhaled","fullItemName":"Scenario: Corticosteroids - inhaled"}]},{"id":"bd9a7839-1db9-5989-b6e2-1dca5e05011d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"911e76ba-1f8e-5933-9443-46079dc58b6e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c1740827-55f4-59ff-be70-58d37950d253","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"89f98a44-5528-5143-a4a4-7191fb4e63a5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d1f364ad-9716-533d-be8e-e76d8756114d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f271d3a7-f87a-5588-ba5e-8a5f5a6f9cb4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ac4dbca5-4c83-52b2-b0ac-a8b7bd478cf0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ccd99bc8-bb83-57ec-be29-e083eabb4915","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"39f35fad-0659-5902-87b2-552b35242d2d","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"30f7eb9b-5d8d-5b35-9e35-63ad15e7e750","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field ec041d32-7b91-4ba5-a45b-414a72b69aa9 --><h3>Previous changes</h3><!-- end field ec041d32-7b91-4ba5-a45b-414a72b69aa9 -->","summary":null,"htmlStringContent":"<!-- begin item 090abd6a-abec-4e5e-9ea8-c9a2d631a63d --><!-- begin field 51a2ce43-0b36-4e7c-a59a-9bd88f54b0b8 --><p><strong>April 2020</strong> — minor update. Advice about using inhaled corticosteroids during the COVID-19 pandemic has been added in line with NICE rapid guidelines <em>COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-inhaled/references/\">NICE, 2020a</a>], and COVID-19 rapid guideline: severe asthma NICE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-inhaled/references/\">NICE, 2020b</a>]. </p><p><strong>July to September 2015 </strong>— reviewed. A literature search was conducted in June 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last version of this topic. There have been no major changes to the recommendations.</p><p><strong>February 2013</strong> — minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012</strong> — minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2011</strong> — minor update. Amended the <em>Drug interactions</em> node to include updated information in the Summary of Product Characteristics for Symbicort Turbohaler<sup> </sup>with regards to an interaction between budesonide and drugs that are potent inhibitors of cytochrome P450. Issued in November 2011.</p><p><strong>May 2011</strong> — minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>September 2010</strong> — minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has reminded prescribers that psychological and behavioural side effects may occur in association with the use of inhaled corticosteroids. Issued in September 2010.</p><p><strong>April to August 2010</strong> — this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 51a2ce43-0b36-4e7c-a59a-9bd88f54b0b8 --><!-- end item 090abd6a-abec-4e5e-9ea8-c9a2d631a63d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}